

# A study of the concentration of ciprofloxacin in the body over time when given by mouth

|  |  |  |
|--|--|--|
| <b>Submission date</b><br>03/06/2008   | <b>Recruitment status</b><br>No longer recruiting              | <input type="checkbox"/> Prospectively registered    |
| <b>Registration date</b><br>10/06/2008 | <b>Overall study status</b><br>Completed                       | <input type="checkbox"/> Protocol                    |
| <b>Last Edited</b><br>02/02/2009       | <b>Condition category</b><br>Nutritional, Metabolic, Endocrine | <input type="checkbox"/> Statistical analysis plan   |
|  |  | <input type="checkbox"/> Results                     |
|  |  | <input type="checkbox"/> Individual participant data |
|  |  | <input type="checkbox"/> Record updated in last year |

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Nahashon Thuo

**Contact details**  
P.O. Box 230  
Kilifi  
Kenya  
80108

## Additional identifiers

**Protocol serial number**  
077092

## Study information

**Scientific Title**  
Population pharmacokinetics of oral ciprofloxacin in children with severe malnutrition

**Study objectives**  
Mortality among children with severe malnutrition has remained high especially for those with proven bacteraemia. The currently recommended antibiotics offer sub-optimal cover for gram negative infections. Ciprofloxacin has good gram negative cover and can be given as an oral

formulation owing to its good oral bioavailability over norfloxacin and good tissue penetration, which give concentrations that are at least equivalent to the minimum inhibitory concentration designated as the breakpoint of bacterial susceptibility in vitro.

It has been used widely in children with cystic fibrosis and immunocompromised children without any significant toxicity. The previous cost of the newer generations of oral quinolones was prohibitive and so pharmacokinetics (PK) in such populations could not be justified on the basis of limited application. The availability of cheaper formulations of the oral quinolones coupled with poor prognosis of children with severe malnutrition and gram negative infection on current standard treatment support the value of this study. No studies have been done on the PK of ciprofloxacin in children with severe malnutrition. This will provide a model to predict PK of ciprofloxacin in this group. Again this data will assist with the future national and international treatment guidelines for children with severe malnutrition.

Please note as of 02/02/2009 this record was amended to include a change to the interventions and a change to the number of participants. Ethics approval has been received for these amendments. Please also note that at this time a public title was added to this record and the initial public title moved to the scientific title field.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Ethics approval received from the Kenya Medical Research Institute (KEMRI) Ethical Review Committee (ERC) on the 27th March 2008 (Scientific Steering Committee [SSC] ref: 1331).

### **Study design**

Single centre, single arm, non-randomised, population PK trial

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Severe acute malnutrition

### **Interventions**

Current information as of 02/02/2009:

In 36 children, ciprofloxacin will be given 2 hours after the child has received his/her first feed and medication. 16 children will have ciprofloxacin administered together with the first feed in order to investigate whether milk based formula diets (F75/F100) alters the pharmacokinetics of ciprofloxacin in children with severe malnutrition. Patients will be given ciprofloxacin orally, 10 mg/kg, twice daily for two days.

The children will be reviewed daily until they are discharged and then on day 28.

Initial information at time of registration:

Children will be divided into three groups based on severity. From each group there will be three subgroups for sampling times for four samples. Patients will be given ciprofloxacin orally, 10 mg/kg, twice daily for two days.

The children will be reviewed daily until they are discharged and then on day 28.

### **Intervention Type**

Drug

### **Phase**

Not Applicable

### **Drug/device/biological/vaccine name(s)**

Ciprofloxacin

### **Primary outcome(s)**

Determine the peak plasma concentrations of ciprofloxacin.

Measured:

Group 1: at 2, 4, 8, 24 hours

Group 2: at 3, 5, 9, 12 hours

Group 3: at 1, 3, 6, 10 hours

### **Key secondary outcome(s)**

Define which co-variables influence the pharmacokinetics of ciprofloxacin in this group of patients:

1. Age, assessed on admission (0 hour)
2. Sex, assessed on admission (0 hour)
3. Anthropometric indices, assessed on admission (0 hour)
4. Haemodynamic status, measured at 0 hour and 48 hour
5. Concomitant medications, reviewed every 4 hours

### **Completion date**

26/03/2009

## **Eligibility**

### **Key inclusion criteria**

1. Aged over 6 months, either sex
2. Consent given
3. Severe malnutrition as defined by weight-for-height Z score (WHZ) less than -3 or bilateral oedema (of kwashiorkor) or mid-upper arm circumference (MUAC) less than 11.0 cm (if greater than 65 cm in length)
4. Able to take and retain oral treatment

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

**Age group**

Child

**Lower age limit**

6 months

**Sex**

All

**Key exclusion criteria**

1. Admission plasma creatinine greater than 300 and evidence of intrinsic renal disease (hypertension or hyperkalaemia)
2. Coexisting bone or joint disease
3. Concurrent use of antacids, ketoconazole, theophylline, corticosteroids
4. Enrolment in another interventional study

**Date of first enrolment**

09/06/2008

**Date of final enrolment**

26/03/2009

**Locations****Countries of recruitment**

Kenya

**Study participating centre**

P.O. Box 230

Kilifi

Kenya

80108

**Sponsor information****Organisation**

Kenya Medical Research Institute (KEMRI) Wellcome Trust Research Programme (Kenya)

**ROR**

<https://ror.org/04r1cxt79>

# Funder(s)

## Funder type

Research organisation

## Funder Name

Kenya Medical Research Institute (KEMRI) Wellcome Trust Research Programme (Kenya) (ref: 077092)

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration